Approval Year
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QL04AB05
Created by
admin on Sat Dec 16 10:14:10 GMT 2023 , Edited by admin on Sat Dec 16 10:14:10 GMT 2023
|
||
|
WHO-ATC |
L04AB05
Created by
admin on Sat Dec 16 10:14:10 GMT 2023 , Edited by admin on Sat Dec 16 10:14:10 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CIMZIA (REFUSED: CROHN DISEASE)
Created by
admin on Sat Dec 16 10:14:10 GMT 2023 , Edited by admin on Sat Dec 16 10:14:10 GMT 2023
|
||
|
NDF-RT |
N0000175610
Created by
admin on Sat Dec 16 10:14:10 GMT 2023 , Edited by admin on Sat Dec 16 10:14:10 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CIMZIA (AUTHORIZED: ARTHRITIS, RHEUMATOID)
Created by
admin on Sat Dec 16 10:14:10 GMT 2023 , Edited by admin on Sat Dec 16 10:14:10 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Certolizumab Pegol
Created by
admin on Sat Dec 16 10:14:10 GMT 2023 , Edited by admin on Sat Dec 16 10:14:10 GMT 2023
|
PRIMARY | |||
|
CERTOLIZUMAB PEGOL
Created by
admin on Sat Dec 16 10:14:10 GMT 2023 , Edited by admin on Sat Dec 16 10:14:10 GMT 2023
|
PRIMARY | |||
|
100000089458
Created by
admin on Sat Dec 16 10:14:10 GMT 2023 , Edited by admin on Sat Dec 16 10:14:10 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201831
Created by
admin on Sat Dec 16 10:14:10 GMT 2023 , Edited by admin on Sat Dec 16 10:14:10 GMT 2023
|
PRIMARY | |||
|
8448
Created by
admin on Sat Dec 16 10:14:10 GMT 2023 , Edited by admin on Sat Dec 16 10:14:10 GMT 2023
|
PRIMARY | |||
|
428863-50-7
Created by
admin on Sat Dec 16 10:14:10 GMT 2023 , Edited by admin on Sat Dec 16 10:14:10 GMT 2023
|
PRIMARY | |||
|
4968
Created by
admin on Sat Dec 16 10:14:10 GMT 2023 , Edited by admin on Sat Dec 16 10:14:10 GMT 2023
|
PRIMARY | |||
|
C468008
Created by
admin on Sat Dec 16 10:14:10 GMT 2023 , Edited by admin on Sat Dec 16 10:14:10 GMT 2023
|
PRIMARY | |||
|
SUB25423
Created by
admin on Sat Dec 16 10:14:10 GMT 2023 , Edited by admin on Sat Dec 16 10:14:10 GMT 2023
|
PRIMARY | |||
|
DB08904
Created by
admin on Sat Dec 16 10:14:10 GMT 2023 , Edited by admin on Sat Dec 16 10:14:10 GMT 2023
|
PRIMARY | |||
|
PP-10
Created by
admin on Sat Dec 16 10:14:10 GMT 2023 , Edited by admin on Sat Dec 16 10:14:10 GMT 2023
|
PRIMARY | |||
|
709271
Created by
admin on Sat Dec 16 10:14:10 GMT 2023 , Edited by admin on Sat Dec 16 10:14:10 GMT 2023
|
PRIMARY | RxNorm | ||
|
UMD07X179E
Created by
admin on Sat Dec 16 10:14:10 GMT 2023 , Edited by admin on Sat Dec 16 10:14:10 GMT 2023
|
PRIMARY | |||
|
m3272
Created by
admin on Sat Dec 16 10:14:10 GMT 2023 , Edited by admin on Sat Dec 16 10:14:10 GMT 2023
|
PRIMARY | Merck Index | ||
|
UMD07X179E
Created by
admin on Sat Dec 16 10:14:10 GMT 2023 , Edited by admin on Sat Dec 16 10:14:10 GMT 2023
|
PRIMARY | |||
|
6774
Created by
admin on Sat Dec 16 10:14:10 GMT 2023 , Edited by admin on Sat Dec 16 10:14:10 GMT 2023
|
PRIMARY | |||
|
C80972
Created by
admin on Sat Dec 16 10:14:10 GMT 2023 , Edited by admin on Sat Dec 16 10:14:10 GMT 2023
|
PRIMARY |
ACTIVE MOIETY